CU20220045A7 - Compuestos derivados sustituidos de pirimidina para el tratamiento y prevención de la infección por vih - Google Patents

Compuestos derivados sustituidos de pirimidina para el tratamiento y prevención de la infección por vih

Info

Publication number
CU20220045A7
CU20220045A7 CU2022000045A CU20220045A CU20220045A7 CU 20220045 A7 CU20220045 A7 CU 20220045A7 CU 2022000045 A CU2022000045 A CU 2022000045A CU 20220045 A CU20220045 A CU 20220045A CU 20220045 A7 CU20220045 A7 CU 20220045A7
Authority
CU
Cuba
Prior art keywords
prevention
treatment
hiv infection
derivative compounds
pyrimidine derivative
Prior art date
Application number
CU2022000045A
Other languages
English (en)
Inventor
Vladimir Nikolaevich Ivanov
Denis Nikolaevich Kazyulkin
Alexander Vitalievich Kurkin
Ekaterina Vladimirovna Manasova
Mikhail Gennadievich Shurygin
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020107455A external-priority patent/RU2780101C2/ru
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of CU20220045A7 publication Critical patent/CU20220045A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a compuestos derivados de pirimidina de fórmula I con propiedades inhibidoras de la replicación del VIH:</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>, útiles para el tratamiento y prevención de las infecciones por el VIH. También se refiere a composiciones farmacéuticas que los contienen.</p>
CU2022000045A 2020-02-19 2021-02-18 Compuestos derivados sustituidos de pirimidina para el tratamiento y prevención de la infección por vih CU20220045A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020107455A RU2780101C2 (ru) 2020-02-19 Противовирусные средства для лечения и профилактики вич-инфекции
PCT/RU2021/000070 WO2021167495A1 (en) 2020-02-19 2021-02-18 Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection

Publications (1)

Publication Number Publication Date
CU20220045A7 true CU20220045A7 (es) 2023-03-07

Family

ID=71741532

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000045A CU20220045A7 (es) 2020-02-19 2021-02-18 Compuestos derivados sustituidos de pirimidina para el tratamiento y prevención de la infección por vih

Country Status (17)

Country Link
US (1) US12485121B2 (es)
EP (1) EP4107156A1 (es)
JP (1) JP2023515080A (es)
KR (1) KR20220129043A (es)
CN (1) CN115279757B (es)
AU (2) AU2021224460A1 (es)
BR (1) BR112022016342A2 (es)
CA (1) CA3158698A1 (es)
CO (1) CO2022013187A2 (es)
CU (1) CU20220045A7 (es)
GE (2) GEAP202415952A (es)
IL (1) IL290285A (es)
JO (1) JOP20220188A1 (es)
PE (2) PE20230559A1 (es)
PH (1) PH12022551944A1 (es)
WO (1) WO2021167495A1 (es)
ZA (1) ZA202207489B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115028527A (zh) * 2022-05-28 2022-09-09 汉瑞药业(荆门)有限公司 一种3-羟甲基-2,2-二甲基环丙基甲酸的制备方法
CN121471233B (zh) * 2025-12-16 2026-08-11 吉林大学 一种新型异噁唑并嘧啶衍生物、药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4858877B2 (ja) 2004-09-28 2012-01-18 エスティー‐エリクソン、ソシエテ、アノニム 電流モード制御ｄｃ−ｄｃコンバータ
US8575342B2 (en) 2004-09-30 2013-11-05 Tibotech Pharmaceuticals Ltd. HIV inhibiting 5-heterocyclyl pyrimidines
ATE520672T1 (de) 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
BRPI0517272A (pt) 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
DK1858861T3 (da) 2005-03-04 2010-11-08 Tibotec Pharm Ltd HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
EP3381916B1 (en) * 2015-11-27 2020-04-15 Taiho Pharmaceutical Co., Ltd. Condensed pyrimidine compound or salt thereof
CN106117242B (zh) * 2016-06-27 2018-08-03 山东大学 四氢噻喃并嘧啶类衍生物及其制备方法与应用
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用

Also Published As

Publication number Publication date
PE20242348A1 (es) 2024-12-16
NZ786735A (en) 2025-08-29
CA3158698A1 (en) 2021-08-26
AU2024200431A1 (en) 2024-02-08
PE20230559A1 (es) 2023-03-31
EP4107156A1 (en) 2022-12-28
JP2023515080A (ja) 2023-04-12
CN115279757A (zh) 2022-11-01
GEAP202415952A (en) 2024-06-10
ZA202207489B (en) 2023-03-29
RU2020107455A (ru) 2020-07-27
CO2022013187A2 (es) 2022-09-20
JOP20220188A1 (ar) 2022-08-15
GEP20247701B (en) 2024-11-25
IL290285A (en) 2022-04-01
WO2021167495A1 (en) 2021-08-26
US20230120294A1 (en) 2023-04-20
RU2020107455A3 (es) 2021-05-05
PH12022551944A1 (en) 2023-10-23
BR112022016342A2 (pt) 2022-10-04
KR20220129043A (ko) 2022-09-22
AU2024200431B2 (en) 2025-10-23
US12485121B2 (en) 2025-12-02
AU2021224460A1 (en) 2022-12-15
CN115279757B (zh) 2026-06-19

Similar Documents

Publication Publication Date Title
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2019002204A1 (es) Compuestos inhibidores del vih.
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
CL2019001495A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih.
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
AR119174A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CR20180092A (es) Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
DOP2015000082A (es) Inhibidores no nucleósidos de la transcriptasa inversa
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CL2021002263A1 (es) Compuestos antibacterianos (solicitud divisional 202001147)
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
MX2018003212A (es) Inhibidores de transcriptasa inversa de nucleosido 4&#39;-substituido y preparaciones de los mismos.
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
AR124868A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CO2022009260A2 (es) Composiciones farmacéuticas oftálmicas
DOP2026000079A (es) Inhibidores del factor b del complemento y usos de los mismos